Abstract
Amrubicin (AMR) is an active drug in patients with relapsed or refractory small cell lung cancer. Severe neutropenia is often observed, and in some patients, subsequent treatment delay and/or dose reduction is often required. We clarified the relationship between the absolute neutrophil count-time profiles and the pharmacokinetic properties of AMR and its active metabolite amrubicinol (AMR-OH) previously, and a therapeutic drug monitoring (TDM) study is ongoing. We have developed and validated a fully-automated analytical method for the measurement of AMR and AMR-OH concentrations in human plasma using LC-MS/MS which can be applied simply to TDM.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
